Efficacy of intralesional bleomycin in recalcitrant warts a study at tertiary care centre

×

Error message

  • User warning: The following module is missing from the file system: module_filter. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /home/ijcmesjournal/public_html/includes/bootstrap.inc).
  • Deprecated function: Function create_function() is deprecated in include_once() (line 1 of /home/ijcmesjournal/public_html/sites/all/themes/bootstrap/templates/system/item-list.func.php).
  • Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in _menu_load_objects() (line 579 of /home/ijcmesjournal/public_html/includes/menu.inc).
  • Deprecated function: Function create_function() is deprecated in include_once() (line 1 of /home/ijcmesjournal/public_html/sites/all/themes/bootstrap/templates/system/status-messages.func.php).
Author: 
Balaji Ganesh J., Kaviarasan PK., Prasad PVS., Kannambal K and Poorana B

Background/Aim: Warts are rough verrucous spiny papules or nodules that can be found on any cutaneous surface. In few patients warts spontaneously regress, whereas others show persistence and progression leading to physical and emotional stress. Several therapeutic approaches like electrosurgery, cryotherapy, keratolytics, vaccines have been used in treating warts, but resistance and recurrences to these therapies has been reported. Bleomycin is an anticancer drug having antitumor, antibacterial and antiviral activity showing promising efficacy in the management of recalcitrant warts. It has gained increasing popularity in the recent past for treatment of warts particularly in palmoplantar and periungual regions as other modalities are not very effective. Hence we evaluated the role of intralesion albleomycin in recalcitrant warts.
Material And Methods: The study group consisted of 30 cases of multiple cutaneous warts. We administered bleomycin which was mixed with 2% lignocaine and injected intralesionally into the warts at an interval of every 3 weeks till the clearance in 30 patients who attended DVL out patient clinic at RMMCH. Ethical clearance was obtained as well as informed consent from all patients.
Results: After completion of 3 sittings at the interval of 3 weeks we observed that the response in common warts was 90%, periungual warts was 85%, while the response in palmar warts was 90% and plantar warts was 76 %.
Conclusion: Our study showed that intralesion albleomycin injection was safe and efficacious in the treatment of multiple recalcitrant cutaneous warts and the bleomycindose for periungual warts needs more visits than cutaneous and palmar warts.

Page: 
465-467
Download PDF: